At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Fluzoparib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ⅰb/Ⅱ Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Fluzoparib, temozolomide, and 1 other intervention for Small Cell Lung Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of the combination of Fluzoparib (SHR-3162) and temozolomide with or without SHR-1316 in small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedMay 22, 2020
Enrollment StartJun 11, 2020
Primary CompletionJan 15, 2022
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 6.1 years ago
Interventions
Fluzoparibdrug
Given PO
temozolomidedrug
Given PO
SHR-1316biological
Given injection